GVGeoffrey A. Vargish

Geoffrey A. Vargish

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Geoffrey A. Vargish has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • Chris McBain

    Section on Cellular and Synaptic Physiology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health

    3 shared publications
  • Kenneth A. Pelkey

    Section on Cellular and Synaptic Physiology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health

    3 shared publications
  • Adam Caccavano

    Section on Cellular and Synaptic Physiology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health

    2 shared publications
  • Anna Vlachos

    Section on Cellular and Synaptic Physiology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health

    2 shared publications
  • Anya Plotnikova

    Laboratory of Neuropsychology, National Institute of Mental Health (NIMH), NIH, Bethesda, MD, 20892 USA

    2 shared publications
  • Arya Mohanty

    Laboratory of Neuropsychology, National Institute of Mental Health (NIMH), NIH, Bethesda, MD, 20892 USA

    2 shared publications

Latest Publications

  • Open Access

    Discrete interneuron subsets participate in GluN1/GluN3A excitatory glycine receptor (eGlyR)-mediated regulation of hippocampal network activity throughout development and evolution

    by June Hoan Kim, Anna Vlachos, Vivek Mahadevan, Adam P Caccavano, Tue Banke, Oliver C Crawley, Ana I Navarro, Xiaoqing Yuan, Daniel Abebe, Steven Hunt, et al.

    Summary: Decades of studies implicating GluN3A N -methyl-D-aspartate receptor (NMDAR) subunits in physiological and pathological function have largely been interpreted through direct regulation of conventional glutamatergic NMDARs. However, emerging evidence indicates that GluN3A frequently assembles with GluN1 forming unconventional glutamate-insensitive NMDARs that operate as native excitatory glycine receptors (eGlyRs). Here we demonstrate that hippocampal somatostatin and neurogliaform interneurons (Sst-INs and NGFCs) express functional eGlyRs from early postnatal through adult ages. In the developing hippocampus eGlyR-mediated excitation of NGFCs with ambient glycine dramatically increases GABAergic tone, with consequences for the generation of giant depolarizing potentials (GDPs). In the mature hippocampus, eGlyR- mediated excitation of Sst-INs regulates sharp wave ripples (SWRs). Finally, we reveal evolutionary conservation of hippocampal Sst-IN eGlyRs and eGlyR- mediated SWR regulation in non-human primates confirming functional eGlyR availability for therapeutic potential in higher species. Our findings underscore that eGlyR mediated regulation of cell and circuit excitability through both cell autonomous and cell non-autonomous mechanisms must be considered to understand GluN3A roles in brain development, plasticity, and disease.


  • Open Access

    Divergent opioid-mediated suppression of inhibition between hippocampus and neocortex across species and development

    by Adam P. Caccavano, Sarah Kimmel, Anna Vlachos, Vivek Mahadevan, June Hoan Kim, Geoffrey Vargish, Ramesh Chittajallu, Edra London, Xiaoqing Yuan, Steven Hunt, et al.

    SUMMARY: Within the adult rodent hippocampus, opioids suppress inhibitory parvalbumin-expressing interneurons (PV-INs), thus disinhibiting local micro-circuits. However, it is unknown if this disinhibitory motif is conserved in other cortical regions, species, or across development. We observed that PV-IN mediated inhibition is robustly suppressed by opioids in hippocampus proper but not primary neocortex in mice and nonhuman primates, with spontaneous inhibitory tone in resected human tissue also following a consistent dichotomy. This hippocampal disinhibitory motif was established in early development when PV-INs and opioids were found to regulate early population activity. Acute opioid-mediated modulation was partially occluded with morphine pretreatment, with implications for the effects of opioids on hippocampal network activity important for learning and memory. Together, these findings demonstrate that PV-INs exhibit a divergence in opioid sensitivity across brain regions that is remarkably conserved across evolution and highlights the underappreciated role of opioids acting through immature PV-INs in shaping hippocampal development.


  • Open Access

    A novel enhancer-AAV approach selectively targeting dentate granule cells

    by Emmie Banks, Claire-Anne Gutekunst, Geoffrey A. Vargish, Anna Eaton, Kenneth A. Pelkey, Chris J. McBain, James Q. Zheng, Viktor Janos Oláh, Matthew Jm Rowan

    Summary: The mammalian brain contains the most diverse array of cell types of any organ, including dozens of neuronal subtypes with distinct anatomical and functional characteristics. The brain leverages these neuron-type-specializations to perform diverse circuit operations and thus execute different behaviors properly. Through the use of Cre lines, access to specific neuron types has steadily improved over past decades. Despite their extraordinary utility, development and cross-breeding of Cre lines is time-consuming and expensive, presenting a significant barrier to entry for many investigators. Furthermore, cell-based therapeutics developed in Cre mice are not clinically translatable. Recently, several AAV vectors utilizing neuron-type-specific regulatory transcriptional sequences (enhancer-AAVs) were developed which overcome these limitations. Using a publicly available RNAseq dataset, we evaluated the potential of several candidate enhancers for neuron-type-specific targeting in the hippocampus. Here we identified a promising enhancer-AAV for targeting dentate granule cells and validated its selectivity in wild-type adult mice.